Digi.Bio
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Digi.Bio - overview
Established
2017
Location
Amsterdam, -, Netherlands
Primary Industry
Biotechnology
About
Digi. Bio is a biotechnology company that specializes in single-cell profiling technology, enhancing the development and efficacy of cell-based therapies by enabling precise measurements of cellular dynamics and therapeutic responses. Founded in 2017 in Amsterdam, Netherlands, Digi. Bio focuses on providing innovative solutions for single-cell analysis.
The company, led by CEO and Founder Federico Muffatto, has secured funding through a SEED round in March 2017, which served as the initial investment target. Digi. Bio primarily offers a platform focused on single-cell profiling technology designed to enhance cell-based therapies. Their core product measures cellular dynamics, interactions, and therapeutic responses at a single-cell level, applicable to various therapeutic modalities, including engineered T cells and antibodies.
The platform serves pharmaceutical companies, biotech firms, and academic research institutions in North America, Europe, and Asia, addressing the demand for precise life sciences technologies. Digi. Bio generates revenue through strategic partnerships and B2B transactions with clients in the biotechnology field. Their business model includes subscription and service agreements for access to their proprietary platform, complemented by technical support and consultation.
Engagements often involve customized assay development and data analytics tools for real-time therapeutic efficacy monitoring, aligning revenue with the complexity of the services provided to clients such as research institutions and pharmaceutical companies. Digi. Bio plans to expand its product offerings and market reach following its SEED funding round in March 2017. The company aims to develop new products that enhance the capabilities of their current platform, although specific release dates have not been disclosed.
They are also looking to penetrate additional geographic markets, particularly targeting expansion into Asia and Europe by 2024. The recent funding will support these product development initiatives and market expansion efforts.
Current Investors
SOSV
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Analytics & Performance Software
Website
www.digi.bio
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Digi.Bio - financials
| Fiscal Year Ended | Dec 31, 2017 |
|---|---|
| Revenue (USD) | - |
| % Revenue Growth (YoY) | - |
| EBITDA (USD) | - |
| Operating Income (USD) | - |
| Operating Margin | - |
| % EBITDA Margin | - |
| NET Income (USD) | - |
| % Net Margin | - |
Digi.Bio - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Member Advisory Board | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.